查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1917823

區塊鏈在臨床試驗市場的應用－2026-2031年預測

Blockchain in Clinical Trials Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計區塊鏈臨床試驗市場將從 2025 年的 153,392,000 美元成長到 2031 年的 508,430,000 美元，複合年成長率為 22.11%。

區塊鏈在臨床試驗中的應用市場是指將分散式帳本技術 (DLT) 應用於提升臨床研究方法的完整性、安全性和效率。這個專業市場利用區塊鏈的核心架構原則——去中心化、不可篡改性、加密安全性和基於共識的檢驗——構建了一個檢驗、透明且防篡改的臨床試驗數據和流程管理系統。它並非單一產品，而是一個基礎技術層，旨在應對多方相關人員、高度監管的臨床研究環境中存在的系統性挑戰。其最終目標是在整個試驗生命週期中提升信任度、協作性和數據品質。

市場對區塊鏈技術的接受度成長源於解決傳統臨床試驗模式中長期存在的挑戰的迫切需求。關鍵的推動因素是對前所未有的資料完整性和可追溯性的需求。區塊鏈不可篡改的帳本為所有試驗數據創建了審核、帶有時間戳記的監管鏈，涵蓋從患者知情同意書、病例報告表到不利事件報告的所有數據。這項獨特特性直接解決了資料篡改、詐欺和無意錯誤的風險，從而增強了監管申報的有效性和科學的可靠性。此外，該技術有望簡化傳統上繁瑣且分散的資料管理。透過在一個統一、可信任的資訊來源上實現申辦者、合約研究組織 (CRO)、研究中心和監管機構之間安全、授權的即時資料共用，區塊鏈減少了資料核對延遲、行政負擔和潛在的差異。

核心價值提案在於以病人為中心和增強信任。區塊鏈透過提供安全透明的機制，賦予參與者自主管理知情同意和控制個人健康資訊存取權限的能力。智慧合約是區塊鏈上的自動執行程式碼，可以自動化知情同意流程中的某些環節，甚至可以為參與者提供直接且合規的獎勵。這種透明度和控制感有望透過建立患者對研究生態系統的信任，從而提高招募率、留存率和整體參與度。

從地理位置來看，北美是開創性和最先進的市場。這主要歸功於其成熟的醫藥研發體系、高度集中的技術創新者，以及對技術試點和討論持開放態度的法規環境。該地區對資料安全（例如HIPAA）的高度重視及其在全球藥物研發中的主導地位，為該領域的早期探索和概念驗證（PoC）開發創造了肥沃的土壤。

儘管區塊鏈具有變革性潛力，但其市場在廣泛商業部署方面仍面臨許多障礙。關鍵挑戰在於，如何將一種新型的去中心化架構深度整合到現有高度複雜且受監管的臨床試驗工作流程和傳統IT系統（例如，電子資料擷取系統（EDC）、臨床試驗管理系統（CTMS））中。如何在不創建新的資料孤島的情況下實現互通性，是一個巨大的技術難題。此外，基於區塊鏈的系統的監管路徑仍不明朗。 FDA和EMA等監管機構正在尋求明確區塊鏈上的資料審核追蹤如何符合現有指南（例如，21 CFR Part 11、ALCOA+原則），以及在去中心化網路中最終由誰承擔責任。處理大規模試驗資料集的可擴展性和效能，以及資料隱私問題（例如，如何使區塊鏈透明度與GDPR的「被遺忘權」保持一致），也是限制區塊鏈應用的重要阻礙因素。

競爭格局尚不成熟且分散，由成熟的企業技術供應商、專注於區塊鏈領域的新創Start-Ups以及製藥公司聯盟組成。主要參與者之間的競爭體現在其底層區塊鏈通訊協定的穩健性、能夠抽象化技術複雜性的方便用戶使用型應用層的開發，以及與行業相關人員建立戰略聯盟的能力。成功不僅取決於技術能力，還取決於深厚的臨床和監管專業知識，以及透過營運效率和風險規避來展現實際投資回報率的能力。

總之，區塊鏈在臨床試驗領域的市場目前仍處於探索和試驗檢驗的關鍵階段，而非大規模應用階段。其成長的驅動力源自於一個概念性邏輯：在一個效率低、價值數十億美元的產業中，人們迫切需要提高透明度、效率和信任度。對於業內人士而言，策略重點應超越理論應用案例，著重解決實際的整合和擴充性挑戰，積極與監管機構合作建立評估框架，並量化諸如縮短週期、降低審核成本和提高數據品質等實際價值。成功取決於一種協作式、聯盟式的模式，這種模式能夠協調所有相關人員的獎勵，並展現其在加快新治療方法上市速度和提高其可靠性方面的實際潛力。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2021-2025 年）和預測資料（2026-2031 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

第5章 按區塊鏈類型分類的臨床試驗區塊鏈市場

  • 介紹
  • 私人的
  • 民眾
  • 聯盟
  • 混合

第6章：區塊鏈在臨床試驗市場的應用

  • 介紹
  • 病患資料管理
  • 臨床資料交換/共用
  • 藥品可追溯性和真實性
  • 智慧合約
  • 其他

7. 區塊鏈在臨床試驗市場的最​​終用戶分佈

  • 介紹
  • 製藥和生物技術公司
  • 研究和學術機構
  • 其他

8. 各地區臨床試驗區塊鏈市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 台灣
    • 其他

第9章：競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第10章：公司簡介

  • IBM
  • Microsoft Corporation
  • Oracle Corporation
  • Accenture PLC
  • Consensys Health
  • Bitfury Group Limited
  • FarmaTrust
  • LabTrace
  • Chronicled
  • iSolve

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 分析方法
  • 簡稱
簡介目錄
Product Code: KSI061615808

Blockchain In Clinical Trials Market is projected to expand at a 22.11% CAGR, attaining USD 508.43 million in 2031 from USD 153.392 million in 2025.

The blockchain in clinical trials market represents the application of distributed ledger technology (DLT) to enhance the integrity, security, and efficiency of the clinical research process. This specialized market involves leveraging blockchain's core architectural principles-decentralization, immutability, cryptographic security, and consensus-based validation-to create verifiable, transparent, and tamper-resistant systems for managing clinical trial data and processes. It is not a singular product but rather a foundational technological layer designed to address systemic challenges in multi-stakeholder, highly regulated clinical research environments. The ultimate goal is to improve trust, collaboration, and data quality across the entire trial lifecycle.

Market adoption is driven by the urgent need to address persistent pain points in traditional clinical trial models. A primary catalyst is the demand for unprecedented data integrity and traceability. Blockchain's immutable ledger creates an auditable, time-stamped chain of custody for all trial data-from patient consent forms and case report forms to adverse event reports. This inherent feature directly combats risks of data manipulation, fraud, and unintentional errors, thereby strengthening regulatory submissions and scientific validity. Furthermore, the technology promises to streamline historically cumbersome and siloed data management. By enabling secure, permissioned real-time data sharing among sponsors, contract research organizations (CROs), sites, and regulators on a single, reconciled source of truth, blockchain can reduce reconciliation delays, administrative overhead, and the potential for discrepancies.

A significant value proposition is the enhancement of patient-centricity and trust. Blockchain can empower participants by providing a secure, transparent mechanism for managing their consent and controlling access to their personal health information. Smart contracts-self-executing code on the blockchain-can automate elements of the consent process and even facilitate direct, compliant incentives to participants. This transparency and perceived control have the potential to improve recruitment, retention, and overall engagement by building patient trust in the research ecosystem.

Geographically, North America has been the pioneering and most advanced market, largely due to its mature pharmaceutical R&D sector, high concentration of technology innovators, and a regulatory environment that has shown openness to technological pilots and discussions. The region's strong emphasis on data security (e.g., HIPAA) and its leading role in global drug development have created a fertile ground for initial exploration and proof-of-concept development in this space.

Despite its transformative potential, the market faces substantial barriers to widespread commercial deployment. The primary challenge is the profound complexity of integrating a novel, decentralized architecture into existing, highly complex, and regulated clinical trial workflows and legacy IT systems (EDC, CTMS, etc.). Achieving interoperability without creating new data silos is a significant technical hurdle. Furthermore, the regulatory pathway for blockchain-based systems remains ambiguous. Regulatory agencies like the FDA and EMA require clarity on how data audit trails on a blockchain satisfy existing guidelines (e.g., 21 CFR Part 11, ALCOA+ principles), and who bears ultimate responsibility in a decentralized network. Scalability and performance for handling large-scale trial data, along with concerns over data privacy (e.g., reconciling blockchain's transparency with GDPR's "right to be forgotten"), also present critical adoption constraints.

The competitive landscape is nascent and fragmented, comprising a mix of established enterprise technology providers, specialized blockchain startups, and consortia formed by pharmaceutical companies. Key players compete on the robustness of their underlying blockchain protocol, the development of user-friendly application layers that abstract the technology's complexity, and the ability to form strategic partnerships with industry stakeholders. Success hinges not just on technological prowess, but on deep domain expertise in clinical operations and regulatory affairs, and the ability to demonstrate tangible return on investment through operational efficiencies and risk mitigation.

In conclusion, the blockchain in clinical trials market is at a pivotal stage of exploration and pilot validation rather than mass implementation. Its growth is conceptually supported by the compelling need for greater transparency, efficiency, and trust in a multi-billion-dollar industry burdened by inefficiency. For industry experts, strategic focus must center on moving beyond theoretical use cases to solving practical integration and scalability challenges, actively engaging with regulators to co-create evaluation frameworks, and quantifying the real-world value in terms of reduced cycle times, lower audit costs, and improved data quality. Success will depend on collaborative, consortium-based approaches that align the incentives of all stakeholders and demonstrate that the technology can deliver concrete improvements to the speed and reliability of bringing new therapies to market.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Blockchain in Clinical Trials Market Segmentation

  • By Blockchain Type
  • Private
  • Public
  • Consortium
  • Hybrid
  • By Application
  • Patient Data Management
  • Clinical Data Exchange & Sharing
  • Drug Traceability & Authenticity
  • Smart Contracts
  • Others
  • By End-User
  • Pharmaceutical & Biotech Companies
  • Research & Academic Institutes
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY BLOCKCHAIN TYPE

  • 5.1. Introduction
  • 5.2. Private
  • 5.3. Public
  • 5.4. Consortium
  • 5.5. Hybrid

6. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Patient Data Management
  • 6.3. Clinical Data Exchange & Sharing
  • 6.4. Drug Tracebility & Authenticity
  • 6.5. Smart Contracts
  • 6.6. Others

7. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical & Biotech Companies
  • 7.3. Research & Academic Institutes
  • 7.4. Others

8. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Italy
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Taiwan
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. IBM
  • 10.2. Microsoft Corporation
  • 10.3. Oracle Corporation
  • 10.4. Accenture PLC
  • 10.5. Consensys Health
  • 10.6. Bitfury Group Limited
  • 10.7. FarmaTrust
  • 10.8. LabTrace
  • 10.9. Chronicled
  • 10.10. iSolve

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations